On the afternoon of March 12, an innovative drug led by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, was launched.The launch meeting for the National Science and Technology Major Project on Drug Development, " Research on Innovative Chemical Drugs for Anti-Alzheimer's Disease Targeting New Mechanisms," was held in Shanghai.

This meeting was conducted strictly in accordance with the special project management standards, systematically deploying the project's overall objectives, technical roadmap planning, task allocation, clinical research layout, and funding management throughout the entire process. (Wanbangde)(002082) The wholly-owned subsidiary Wanbangde Pharmaceutical Group, together with the project lead unit, cooperating research institutions and industry experts, gathered together to discuss the details of the project implementation and build consensus on research and development.

Alzheimer's disease is the most common type of dementia in clinical practice and also the most prevalent neurodegenerative disease. Its main manifestations include progressive decline in memory, judgment, and language abilities, ultimately leading to loss of thinking and motor skills, and inability to care for oneself. (Based on data from Renji Hospital affiliated with Shanghai Jiao Tong University.)According to the "China Alzheimer's Disease Report 2025" published in General Psychiatry in collaboration with several domestic medical and research institutions, there are nearly 17 million patients with Alzheimer's disease and related dementia in China.

As a globally prevalent neurodegenerative disease, Alzheimer's disease has seriously threatened the health of middle-aged and elderly people. Current treatments have limitations, making the development of innovative drugs with novel mechanisms a key focus of the industry. On December 31, 2024, the National Health Commission and the Ministry of Education...The Ministry of Education, the Ministry of Science and Technology, and 15 other departments jointly issued the "National Action Plan for Addressing Alzheimer's Disease (2024-2030)," which aims to build a full-chain action framework from top-level design to grassroots implementation, consisting of "policies, tasks, indicators, and special projects."

The launch of this national key science and technology project focuses on the research and development of innovative chemical drugs targeting new mechanisms. It aims to break through existing technological bottlenecks, build a more complete drug research and development system for Alzheimer's disease, and provide patients with safer and more effective new treatment options. It is an important step for my country's pharmaceutical industry to overcome major diseases and achieve independent innovation.

In January 2026, Wanbangde announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group, had been selected for the National Science and Technology Major Project for Innovative Drug Development, led by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and had received project approval from the China Biotechnology Development Center of the National Health Commission. Wanbangde Pharmaceutical is undertaking the "Industrialization Preparation and Clinical Research of Huperzine A Controlled-Release Tablets," which is an important component of the "Improvement of Clinical Evaluation Indicators and Clinical Research of Innovative Varieties" under this project.

Wanbangde stated that being selected for the National Science and Technology Major Project is a high recognition from the industry of Wanbangde Pharmaceutical Group's R&D strength, compliance management capabilities, and industrialization level. As a company that has been deeply involved in the pharmaceutical industry for two decades, Wanbangde has always focused on unmet clinical needs, accumulating solid technical reserves and R&D experience in the fields of central nervous system and cardiovascular and cerebrovascular diseases, and building a complete innovative drug R&D chain system.

https://finance.eastmoney.com/a/202603133670721865.html